论文部分内容阅读
FⅧ抗体的产生是血友病甲患者治疗过程中的一种严重并发症。本文报道了治疗这种并发症的新方法。开始治疗时,先静注FⅧ、环磷酰胺和IgG,联合疗法,然后继续给予FⅧ正规预防性治疗。具体方法如下:首先静注环磷酰胺,每日12-15mg/kg,连用2天(在输注FⅧ前立即予以第1剂),然后改为口服,每日2 3mg/kg,连用8 10日;FⅧ初次剂量以足以中和这个抑制剂为度,然后将FⅧ凝集活性提高到40 100IU/dL,接着每8-12小时给药1次,使血中的FⅧ凝集活性的浓度维持在30-80IU/dL。当FⅧ的浓度下降时,FⅧ的每日用量就应当增加,可用纯度很高、浓缩且已灭活病毒的商品FⅧ,缩短给药时间;IgG的初次剂量为2.5-5g,在FⅧ首次负荷量给
The production of F Ⅷ antibodies is a serious complication in the treatment of hemophilia A patients. This article reports on new ways to treat this complication. Start treatment, the first intravenous injection of F Ⅷ, cyclophosphamide and IgG, combination therapy, and then continue to give F VIII regular preventive treatment. Specific methods are as follows: first intravenous cyclophosphamide, daily 12-15mg / kg, once every 2 days (immediately before the FⅧ infusion of the first dose), and then changed to oral, daily 2 3mg / kg, with 8 10 Day; the initial dose of F Ⅷ is sufficient to neutralize the inhibitor; then the F Ⅷ agglutination activity is increased to 40 100 IU / dL followed by every 8-12 hours administration to maintain the concentration of F Ⅷ -agglutinating activity in the blood at 30 -80IU / dL. When the concentration of F Ⅷ decreased, the daily dosage of F Ⅷ should be increased, available high purity, concentrated and inactivated products of the virus FVIII, shorten the dosing time; IgG initial dose of 2.5-5g, F Ⅷ first load give